RxDoctor Payments Data

Samuel Yakish, DO

Cardiovascular Disease · Beaver, PANPI 1932338316

Payments from drug & device makers

$942in general payments, 2019–2025

Across 54 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$110
  • E.r. Squibb & Sons, L.L.C.$102
  • Amgen$91
  • Heartflow, Inc.$89
  • Shockwave Medical, Inc$80
  • Novartis$62
  • plus $407 from 16 others

What the payments were for

  • Food & beverage$92198%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$942 in reported general payments places this provider in the 35th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$125,813
Medicare patients
1,191
Services billed
2,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban698$683,873
EntrestoSacubitril/Valsartan282$308,655
VyndamaxTafamidis13$286,371
XareltoRivaroxaban308$269,066
MultaqDronedarone Hcl62$72,088
FarxigaDapagliflozin Propanediol75$60,193
Repatha SureclickEvolocumab63$59,971
JardianceEmpagliflozin43$39,364
BrilintaTicagrelor18$13,408
Metoprolol Succinate762$10,489
Rosuvastatin Calcium720$9,139
Valsartan335$8,609
Diltiazem 24hr Er (Cd)Diltiazem Hcl267$7,694
Atorvastatin Calcium715$7,426
VascepaIcosapent Ethyl16$5,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$44$970,244711 claims
NovartisEntresto$62$308,655282 claims
Johnson & JohnsonXarelto$40$269,066308 claims
AstraZenecaFarxiga, Brilinta$110$73,60193 claims
Sanofi-aventis U.S. LLCMultaq$32$72,08862 claims
Boehringer IngelheimJardiance$19$39,36443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Beaver

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →